Effect of neoadjuvant radiotherapy on survival of non-metastatic Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis

CURRENT STATUS: Under Review

Dan Wang, Chongshun Liu, Yuan Zhou, Tingyu Yan, Chenglong Li, Qionghui Yang, Yang Xu, Lilan Zhao, Qian Pei, Fengbo Tan, Cenap Güngör, Yuqiang Li

Dan Wang
Universitatsklinikum Hamburg-Eppendorf
ORCiD: https://orcid.org/0000-0001-8388-9842

Chongshun Liu
Xiangya Hospital Central South University

Yuan Zhou
George Washington Middle School

Tingyu Yan
Fourth Affiliated Hospital of China Medical University

Chenglong Li
Xiangya Hospital Central South University

Qionghui Yang
Wenzhou Medical College Affiliated Yueqing Hospital

Yang Xu
Universitatsklinikum Hamburg-Eppendorf

Lilan Zhao
Fujian Provincial Hospital

Qian Pei
Xiangya Hospital Central South University

Fengbo Tan
Xiangya Hospital Central South University

Cenap Güngör
Universitatsklinikum Hamburg-Eppendorf

Yuqiang Li
University Medical Center Hamburg-Eppendorf

Corresponding Author
liyuqiang22@yeah.net
Prescreen

10.21203/rs.3.rs-21437/v2

Subject Areas

Oncology  Nuclear Medicine & Medical Imaging

Keywords

Neoadjuvant radiotherapy, Pancreatic Ductal Adenocarcinoma, Overall survival, SEER, Propensity score matching
Abstract

Background: Neoadjuvant radiotherapy has been shown to improve marginal negative resection and local control of Pancreatic Ductal Adenocarcinoma (PDAC). However, whether it improves overall survival (OS) in patients with non-metastatic PDAC remains controversial. Therefore, the purpose of this study was to analyze the benefits of only surgery, neoadjuvant radiotherapy, adjuvant radiotherapy, and surgery plus chemotherapy for OS in patients with non-metastatic PDAC.

Methods: PDAC diagnosed by surgical histopathology in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2016 was selected. Kaplan-Meier analysis was used to compare the prognosis of patients with different treatments. Cox proportional risk model was used to analyze independent predictors of OS. Propensity score matching (PSM) was used to analyze the tumor prognosis of different treatment methods.

Results: Before PSM analysis, the OS of surgery plus chemotherapy (HRs = 0.896, 95% CIs, 0.827-0.970; P=0.007) were significantly better than the other three treatments for stage T1-3N0M0 PDAC patients. For stage T1-3N+M0 patients, adjuvant radiotherapy (HRs=0.613, 95% CIs, 0.579-0.649; P< 0.001) had significantly better OS than surgery plus chemotherapy and neoadjuvant radiotherapy. For stage T4N0M0 patients, neoadjuvant radiotherapy (HRs=0.482, 95% CIs, 0.347-0.670; P < 0.001) had significantly better OS than surgery plus chemotherapy and adjuvant radiotherapy. For stage T4N+M0 patients, neoadjuvant radiotherapy (HRs=0.338, 95% CIs, 0.215-0.532; P < 0.001) had significantly longer OS than adjuvant radiotherapy and surgery plus chemotherapy. Even after PSM, Chemotherapy plus surgery was still the best treatment for T1-3N0M0 patients. Postoperative adjuvant radiotherapy had the best prognosis among T1-3N+M0 patients, and neoadjuvant radiotherapy was the best treatment for T4 patients.

Conclusions: For patients with non-metastatic PDAC, neoadjuvant radiotherapy, adjuvant radiotherapy and surgery plus chemotherapy were superior to only surgery in OS. For patients with stage T4 non-metastatic PDAC, neoadjuvant radiotherapy had the potential to be strongly recommended over adjuvant radiotherapy and surgery plus chemotherapy. However, neoadjuvant radiotherapy failed to benefit the survival of T1-3N0M0 stage patients, and surgery plus chemotherapy was preferred. For T1-3N+M0, neoadjuvant radiotherapy had no obvious advantage over adjuvant radiotherapy or surgery plus chemotherapy in OS, and adjuvant radiotherapy was more recommended.

Background

Pancreatic Ductal Adenocarcinoma (PDAC) is a highly malignant tumor with a 5-year survival of about 7 percent and is on pace to become the second leading cause of cancer-related death in the United States by 2030\(^1,2\). The main reasons for this frustrating survival are the lack of specific diagnostic methods in early PDAC, the high aggressiveness of the tumor, and the early metastasis\(^3,4\). More than 80 percent of PDAC patients already have locally advanced unresectable or metastatic disease at the time of diagnosis\(^5\). Moreover, only about 20 percent of PDAC patients who undergo surgical resection achieve long-term remission, which may be related to the high rate of recurrence after surgery\(^6\).

Neoadjuvant therapy is gaining more and more attention from physicians and scholars due to the dismal survival. Based on a retrospective analysis of significant adjuvant chemotherapy studies in the 1970s, Frei firstly proposed the concept of neoadjuvant therapy (chemotherapy before surgery), which extended disease-free survival in 1982\(^7\). Then, the further study of neoadjuvant therapy included preoperative radiotherapy and chemoradiotherapy. In 1990, the term of neoadjuvant therapy was first used in PDAC. Fox Chase cancer center reported that neoadjuvant chemotherapy and radiotherapy improved the resectability of locally advanced PDAC\(^8\). Moreover, the treatment model for PDAC was changed from "surgical-first" to "multi-disciplinary team" (MDT) with advances in medical technology and treatment concepts in the past decades\(^9\). It is widely recognized regarding the application of neoadjuvant chemotherapy for patients with PDAC today\(^10,11\). However, the role of
neoadjuvant radiotherapy in PDAC is still under debate due to the lack of relatively reliable data. Currently, neoadjuvant radiotherapy is mainly used for borderline resectable PDAC and locally advanced PDAC since which may improve the marginal negative resection rate and local control rate\textsuperscript{12, 13}. However, it is unclear whether neoadjuvant radiotherapy improve survival of patients with PDAC. In addition, it is still highly controversial and requires further discussion whether patients with initially resectable PDAC can get benefit from neoadjuvant radiotherapy.

The Surveillance, Epidemiology, and End Results (SEER) Program collects data on cancer diagnosis, treatment, and survival for approximately 30% of the U.S. population. We attempted to use the SEER database to analyze the effects of different treatment methods including surgery-limited, neoadjuvant radiotherapy, adjuvant radiotherapy and surgery plus chemotherapy on overall survival (OS) in patients with non-metastatic PDAC.

**Materials And Methods**

**Data source**

The cohort used in this study was created from custom data (additional treatment fields) from SEER 18 Registries, and a report was submitted in November 2018 (varied from 1973 to 2016). PDAC diagnosed by surgical histopathology between 2004 and 2016 was selected. In addition, we included basic patient information, detailed clinical staging data, as well as follow-up information, tumor size, and treatment options. Combined with tumor size, T and N staging were recorded on the basis of the 8th edition of TNM staging system. The study was limited to patients with non-metastatic PDAC (any T with any N and M0). After excluding patients who had not undergone surgery and classifying radiotherapy as "no radiation", "radiation after surgery", "radiation prior to surgery" and "no/unknown", 21030 patients were contained in the study (Figure 1). The patients were divided into the following four groups according to the treatment methods: 1. Only surgery group (No radiation or chemotherapy); 2. Surgery + chemotherapy group (without radiation); 3. Neoadjuvant radiotherapy group (Neoadjuvant radiotherapy + surgery with or without chemotherapy); 4. Adjuvant radiotherapy group (surgery + adjuvant radiotherapy with or without chemotherapy). The International Study Group on Pancreatic Surgery (ISGPS) consensus recommended that the number of lymph nodes examined should be at least > 15. Therefore, the number of regional nodes examined was divided into three groups: <15, \( \geq 15 \) and unknown.

**Statistical analyses**

Chi-square test was utilized to compare the classification data. Kaplan-Meier method was used to estimate the survival probability and log-rank test was applied to evaluate the significance difference of OS. Only variables significantly associated with survival in univariate Cox analysis were contained in multivariate Cox analysis. Cox proportional risk model was used to analyze the relationship between patients' clinical characteristics and treatment methods and their survival. Univariate and multivariate models were used to assess the Hazard ratios (HRs) and 95% confidence interval (CIs). The oncological outcomes of different treatments were analyzed by propensity score matching (PSM) analysis. SPSS 25.0 (IBM, Armonk, NY, USA) was used for statistical analysis in this study, and all p values less than 0.05 were statistically significant.

**Results**

**Basic characteristics of the patients**

The basic demographic characteristics of all the patients in this study were shown in Table 1. The majority of the patients were married and Caucasians. 55.17% of target population were over 65 years old and about 50.68% were males. Most of the patients (64.56%) had tumor lesions in the head of the pancreas. Moderately differentiated tumors (41.26%) constituted the majority of the population. Among the 21,030 patients, most of
them were stage T2, accounting for 50.87% (10699 patients), and about 4.60% (968 patients) were stage T4. In terms of treatment regimen, about 42.33% of patients only were managed with surgical treatment, about 30.37% received surgery plus chemotherapy, about 23.61% received postoperative adjuvant radiotherapy, and only about 3.69% underwent neoadjuvant radiotherapy.

Survival Analysis Before Propensity Score Matching

Using univariate and multivariate Cox proportional risk analysis for the total population (Table 2), uninsured status, single status, advanced age (≥65 years old), pancreatic head tumor, high tumor grade, tumor T, N stage, therapy methods and regional nodes examined <15 were all relevant to poor prognosis (all P < 0.001). The Kaplan Meier curve of overall survival in PDAC patients were shown in Figure 2. For patients with non-metastatic PDAC, neoadjuvant radiotherapy, adjuvant radiotherapy and surgery plus chemotherapy had significantly better OS than surgery alone (P < 0.001). After adjusting for insurance status, marital status, age, race, gender, tumor site, tumor grade, T stage, N stage and regional nodes examined, multivariate Cox analysis of different treatment methods was performed, and the influence of each group on OS was shown in table 3. The mean 1-, 3-year survival rates for PDAC patients were shown in table 4.

The OS of surgery plus chemotherapy (HRs =0.896, 95%CIs, 0.827-0.970; P=0.007) were significantly better than the other three treatments in stage T1-3N0M0 PDAC patients. Adjuvant radiotherapy (HRs=0.950; 95% CIs, 0.874-1.032; P=0.223), and only surgery had similar OS results. However, neoadjuvant radiotherapy (HRs = 1.171;95% CIs, 1.019-1.347; P=0.027) seems to be a risk factor for OS. The median survival for only surgery, surgery plus chemotherapy, neoadjuvant radiotherapy and adjuvant radiotherapy was 21moths, 25moths, 19moths, 24moths, respectively. Adjuvant radiotherapy (HRs=0.613, 95% CIs, 0.579-0.649; P< 0.001) had significantly better OS results than surgery plus chemotherapy (HRs=0.686; 95% CIs, 0.649-0.726;P < 0.001) and neoadjuvant radiotherapy (HRs=0.751; 95% CIs, 0.635-0.887; P=0.001) in stage T1-3N+M0 patients, with median survival of 19 moths, 15 moths, and 16 moths, respectively. Specially, for stage T4N0M0 patients, neoadjuvant radiotherapy (HRs=0.482, 95% CIs, 0.347-0.670; P < 0.001) had significantly better OS outcomes than surgery plus chemotherapy (HRs=0.588; 95% CIs, 0.424-0.814; P=0.001) and adjuvant radiotherapy (HRs=0.858; 95% CIs, 0.621-1.185; P=0.353), with median survival of 20 moths, 17 moths, and 14 moths, respectively. Similarly, for stage T4N+M0 patients, neoadjuvant radiotherapy (HRs=0.338, 95% CIs, 0.215-0.532; P < 0.001) had significantly longer OS outcomes than adjuvant radiotherapy (HRs=0.430; 95% CIs, 0.334-0.554; P < 0.001) and surgery plus chemotherapy (HRs=0.530; 95% CIs, 0.411-0.683; P < 0.001), with median survival of 17 moths, 16 moths, and 10 moths, respectively.

Survival Analysis After Propensity Score Matching

The balanced population of the neoadjuvant radiotherapy group and the only surgery group(n=296), the neoadjuvant radiotherapy group and the adjuvant radiotherapy group(n=208), the neoadjuvant radiotherapy group and the surgery plus chemotherapy group(n=288) were obtained by multiple 1:1 propensity score matching for stage T1-3N0M0 PDAC patients. Before and after the PSM, the results of univariate and multivariate analyses of OS in different groups were shown in table 5. The OS of the neoadjuvant radiotherapy group was no better than that of the adjuvant radiotherapy group(HRs=0.807; 95% CIs, 0.649-1.035; P =0.125) and the only surgery group(HRs=1.164; 95% CIs, 0.934-1.449; P =0.176), while the OS of the surgery plus chemotherapy group was better than that of the neoadjuvant radiotherapy group(HRs=1.280; 95% CIs, 1.045-1.574; P =0.025) in stage T1-3N0M0 PDAC patients.

Similarly, the 1:1 propensity score matching was used to obtain the balanced population of the neoadjuvant radiotherapy group and the only surgery group(n=155), neoadjuvant radiotherapy group and the adjuvant radiotherapy group (n=153), neoadjuvant radiotherapy group and the surgery plus chemotherapy group (n=166) in stage T1-3N+M0 PDAC patients. The OS of the neoadjuvant radiotherapy group was better than that of the only surgery group (HRs=0.618; 95% CIs, 0.429-0.863; P =0.036), but there was no difference with that of the operation plus chemotherapy group (HRs=1.083; 95% CIs, 0.838-1.400; P =0.541). The adjuvant
radiotherapy group had the best prognosis (HRs=1.364; 95% CIs, 1.046-1.777; P =0.022).

The 1:1 propensity score matching was used to obtain the balanced population of the neoadjuvant radiotherapy group and the only surgery group (n=104), neoadjuvant radiotherapy group and the adjuvant radiotherapy group (n=102), neoadjuvant radiotherapy group and the surgery plus chemotherapy group (n=138) in stage T4 PDAC patients. The OS of neoadjuvant radiotherapy group was better than that of only surgery group (HRs=0.466; 95% CIs, 0.331-0.657; P <0.001), adjuvant radiotherapy group (HRs=0.589; 95% CIs, 0.419-0.830; P =0.002) and surgery plus chemotherapy group (HRs=0.707; 95% CIs, 0.519-0.963; P =0.028). The Kaplan-Meier curve of overall survival of PDAC patients after PSM were shown in figure 3.

Discussion

The surgical approach for PDAC mainly depends on the anatomical location of the tumor. Although the surgical resection rate and surgical safety of PDAC have been significantly improved, and the incidence of serious complications during perioperative period has been significantly reduced in the past 30 years, the main goal still remains the same: removal of all lesions visible to the naked eye and microscopically within the pancreas and drainage of the lymph nodes, known as marginal negative or R0 resection. However, even after R0 resection, the prognosis of PDAC is not significantly improved, and the treatment of PDAC remains extremely challenging. In this study, patients with non-metastatic PDAC who received surgery alone had the worst prognosis. The main reason for this poor prognosis is local recurrence or distant metastasis of PDAC after surgery, which is a key factor affecting the long-term survival of patients. This showed that only surgical treatment of PDAC is far from enough, and we need to combine systematic adjuvant therapy. Therefore, the application value of neoadjuvant radiotherapy in PDAC has gradually become a hot topic, but there is still a big controversy.

The focus of this study was to determine whether neoadjuvant radiotherapy had a better effect on OS than postoperative radiotherapy, but the existing evidence remains controversial. Currently, it is generally accepted that neoadjuvant radiotherapy is superior to adjuvant radiotherapy mainly related to tumor response and preservation of normal tissues, including the following points. (1). The goal of neoadjuvant radiotherapy is to reduce the stage of the tumor and, in combination with R0 resection, increase the chance of survival. With effective treatment, a percentage of potentially unresectable tumors may be reduced in staging in order to be surgically resectable. (2). Neoadjuvant radiotherapy is more effective on well-oxygenated cells that cannot be surgically removed. (3). In approximately 25% of patients, postoperative adjuvant radiotherapy may be affected due to delayed postoperative recovery. However, delayed postoperative recovery does not affect the implementation of neoadjuvant radiotherapy. (4). The use of neoadjuvant radiotherapy may help identify PDAC patients at high risk of early metastasis.

Therefore, neoadjuvant radiotherapy is considered to be applicable to borderline resectable PDAC and locally advanced PDAC. Some studies demonstrated that neoadjuvant radiotherapy can improve the R0 resection rate and the prognosis of patients with borderline resectable PDAC. After neoadjuvant radiotherapy, the median rate of resection and R0 resection of PDAC patients can reach 68% and 89% respectively. For patients who received neoadjuvant therapy and underwent surgical resection, the median OS range was 15.6 to 35 months. Compared with the group without neoadjuvant radiotherapy, the difference in median OS was statistically significant.

In this study, patients with non-metastatic PDAC were divided into T1-3N0M0, T1-3N+M0, T4N0M0, T4N+M0 according to TNM stages, and the effects of different treatment regimens including neoadjuvant radiotherapy on the prognosis were analyzed. The results proved that neoadjuvant radiotherapy improves OS for T1-4N+M0/T4N0M0 PDAC patients. Moreover, for T4 patients, the effect of neoadjuvant radiotherapy on OS was significantly better than that of adjuvant radiotherapy and surgery plus chemotherapy. Therefore, the necessity of neoadjuvant radiotherapy should be emphasized in clinical practice for PDAC patients with stage T4.

However, the survival of T1-3N0M0 patients couldn’t benefit from neoadjuvant radiotherapy according to the results of this study. Some scholars also questioned the use of neoadjuvant radiotherapy in early PDAC. Patients with resectable PDAC can initially be surgically removed, but neoadjuvant radiotherapy may delay the patient’s surgical opportunity, making the lesions that could have been resected with R0 become unresectable or even
distant metastases\textsuperscript{17}. Especially in the process of neoadjuvant radiotherapy, if the patient has serious complications, such as biliary tract obstruction, this may aggravate the development of the disease, or even make the patient's physical condition worse, not suitable for surgical treatment. Another problem that must be considered is that, unlike surgery, the initiation of neoadjuvant radiotherapy requires definite pathological results. Given the anatomical location and structure of the tumor, biopsy is sometimes difficult to perform and may delay treatment. The specificity of endoscopic ultrasound-guided biopsy is 96 percent, but the sensitivity is only 85.92 percent and repeated examinations are required in 11 percent of cases\textsuperscript{18}.

A prospective, randomized, controlled phase II trial in Germany comparing neoadjuvant chemoradiotherapy with surgical priority for resectable pancreatic cancer was prematurely discontinued after 73 patients were enrolled. The existing results showed that there was no significant difference in R0 removal rate and median overall survival time between the two groups\textsuperscript{19}. A meta-analysis published in 2019 included 11 clinical studies involving 2666 patients from the university of Texas southwestern medical center, Montefiore medical center, Erlangen university hospital, Germany, Tohoku university school of medicine, Japan, and others. The results showed that the R0 resection rate was improved in patients of resectable PDAC treated with neoadjuvant radiotherapy, but the overall survival time of the patients was not significantly increased\textsuperscript{20}. Combined with the results of this study, the overall survival of surgery plus chemotherapy is significantly better than neoadjuvant radiotherapy and adjuvant radiotherapy, so it is recommended that patients with T1-3N0M0 should choose surgery plus chemotherapy as the priority.

A consensus has been reached on the mode of systemic therapy for PDAC under MDT\textsuperscript{21}. For borderline resectable and locally advanced PDAC, neoadjuvant radiotherapy may transform patients who cannot be R0 resected or even inoperable into R0 resectable patients, thus extending survival time and benefiting the patients. In this study, a combination of neoadjuvant radiotherapy was recommended for patients with stage T4 PDAC. Whether neoadjuvant therapy can benefit patients with early resectable PDAC is still controversial. Our study suggested that T1-3N0M0 stage PDAC patients were preferred to receive surgery plus chemotherapy, while neoadjuvant radiotherapy was not recommended. In addition, T1-3N+M0 stage PDAC patients were preferentially recommended postoperative adjuvant radiotherapy. However, this study is only a retrospective analysis from a large database, and the results need to be further verified by prospective experiments. With the development of large clinical trials, high level of evidence-based medical evidence will continue to be presented, and the understanding of neoadjuvant radiotherapy for PDAC will be deepened, which may lead to a consensus on the existing controversies and treatment options in the future.

Similar to other studies using the SEER database as a data source, our study has limitations and requires careful interpretation of the results. First, while the SEER data included information about surgery, radiation, and chemotherapy, the details of these treatments (such as surgical margins, radiation dose, chemotherapy regiments, and chemotherapy sequence) were not recorded in the database. Second, the SEER database lacks some key clinical information that may be important for prognosis, such as tumor markers (CA19-9), the relationships between tumor and important blood vessels, and so on.

**Conclusions**

In summary, this retrospective study analyzed SEER database cases from 2004 to 2016 and made the following recommendations: 1. Among patients with non-metastatic PDAC, stage T1-4N+M0/T4N0M0 patients who received neoadjuvant radiotherapy, adjuvant radiotherapy, and surgery plus chemotherapy had longer OS than those who received surgery alone, while stage T1-3N0M0 patients did not benefit from neoadjuvant radiotherapy. 2. For patients with stage T1-3N0M0, surgery plus chemotherapy is clinically recommended as the preferred treatment. 3. For PDAC patients with stage T1-3N+M0, postoperative adjuvant radiotherapy has a better prognosis and adjuvant radiotherapy is preferred. 4. For stage T4 patients, neoadjuvant radiotherapy had significantly longer OS than adjuvant radiotherapy and surgery plus chemotherapy, which may be appropriate for guidelines to adopt a more proactive stance on using of neoadjuvant radiotherapy for stage T4 PDAC patients.
**Abbreviations**

PDAC: Pancreatic Ductal Adenocarcinoma; OS: Overall Survival; SEER: Surveillance, Epidemiology, and End Results; CIs: Confidence intervals; HRs: Hazard ratios; MDT: Multi-disciplinary team; ISGPS: International Study Group on Pancreatic Surgery; US: United States; PSM: Propensity score matching

**Declarations**

**Ethics approval and consent to participate:**

This study is based on a retrospective analysis of the SEER database. There is no identifiable patient information in the SEER database, and all data is anonymous. Therefore, written informed consent was not required for this study. The survey was conducted in accordance with the ethical standards of the Helsinki Declaration and national and international norms. This study was approved by the institutional review board of our hospital.

**Consent for publication**

Not applicable

**Availability of data and materials**

The data from this study is publicly available in the national cancer institute's Surveillance, Epidemiology, and End Results (SEER) database at [https://seer.cancer.gov/](https://seer.cancer.gov/).

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study has been supported by the National Nature Science Foundation of China (81702956).

**Authors' contributions**

Conceptualization: Dan Wang, Yuqiang Li, Cenap Güngör;
Data curation: Chongshun Liu, Tingyu Yan, Chenglong Li, Qionghui Yang
Formal analysis: Dan Wang, Yang Xu, Lilan Zhao, Qian Pei, Fengbo Tan
Methodology: Dan Wang, Yuqiang Li, Qian Pei, Fengbo Tan
Writing-original draft: Dan Wang
Writing-review & editing: Yuqiang Li, Yuan Zhou, Cenap Güngör
All the authors read and approved the final manuscript.

Acknowledgements

We thank the SEER program for providing this data. The author would like to thank academic editors and anonymous reviewers for their constructive comments.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921.
3. Kenner BJ. Early Detection of Pancreatic Cancer: The Role of Depression and Anxiety as a Precursor for Disease. Pancreas. 2018;47(4):363-367.
4. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-1117.
5. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-1617.
6. Tsai S, Evans DB. Therapeutic Advances in Localized Pancreatic Cancer. Jama Surg. 2016;151(9):862-868.
7. Du W, Li C, Wang H, et al. Effect of neoadjuvant chemotherapy on sevoflurane MAC-BAR value of patients undergoing radical stomach carcinoma surgery. Int J Clin Exp Med. 2015;8(4):5649-5657.
8. Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther. 2010; 3:111-127.
9. Gedge K. Pancreatic cancer: a symptomless killer. J Perioper Pract. 2017;27(7-8):158-161.
10. Youngwirth LM, Nussbaum DP, Thomas S, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. J Surg Oncol. 2017;116(2):127-132.
11. Hackert T, Sachsenmaier M, Hinz U, et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg. 2016;264(3):457-463.
12. Chung SY, Chang JS, Lee BM, Kim KH, Lee Kj, Seong J. Dose escalation in locally advanced pancreatic cancer patients receiving radical chemoradiotherapy. Radiother Oncol. 2017;123(3):438-445.
13. Greenblatt DY, Kelly Kj, Rajamanickam V, et al. Preoperative factors predict perioperative morbidity and mortality after pancreatectoduodenectomy. Ann Surg Oncol. 2011;18(8):2126-2135.
14. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128(6):1626-1641.
15. Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195(3):318-321.
16. Satoi S, Yanagimoto H, Toyokawa H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas. 2009;38(3):282-288.
17. Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Chiaro MD. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245.
18. Kitano M, Yoshida T, Itonaga M, Tamura T, Hatamaru K, Yamashita Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol. 2019;54(1):19-32.
19. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7-16.
20. Ren X, Wei X, Ding Y, et al. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review. Onco Targets Ther. 2019;12:733-744.
21. Tempero M. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017;15(5S):723-725.
| Characteristics          | Level              | Number (%)  |
|-------------------------|--------------------|-------------|
| Insurance Recode        | Insured            | 17218(81.87%) |
|                         | No/unknown         | 3812(18.13%) |
| Marital status          | Married            | 13291(63.20%) |
|                         | Single             | 6984(33.21%)  |
|                         | Unknown            | 755(3.59%) |
| Age, years              | < 65               | 9427(44.83%)  |
|                         | ≥ 65               | 11603(55.17%) |
| Race recode             | White              | 17170(81.65%) |
|                         | Other              | 3860(18.35%) |
| Sex                     | Male               | 10657(50.68%) |
|                         | Female             | 10373(49.32%) |
| Tumor site              | Pancreas Head      | 13576(64.56%) |
|                         | Pancreas Body Tail | 5175(24.61%) |
|                         | Pancreas Other     | 2279(10.83%) |
| Grade                   | I                  | 4147(19.72%) |
|                         | II                 | 8677(41.26%) |
|                         | III/IV             | 6075(28.89%) |
|                         | Unknown            | 2131(10.13%) |
| T stage                 | T1                 | 4242(20.17%) |
|                         | T2                 | 10699(50.87%) |
|                         | T3                 | 5121(24.36%) |
|                         | T4                 | 968(4.60%) |
| N stage                 | N0                 | 9467(45.02%) |
|                         | N1                 | 7400(35.19%) |
|                         | N2                 | 4163(19.79%) |
| Treatment methods       | Only surgery       | 8903(42.33%) |
|                         | Surgery + chemotherapy | 6386(30.37%) |
|                         | Neoadjuvant radiotherapy | 776(3.69%) |
|                         | Adjuvant radiotherapy | 4965(23.61%) |
| Regional nodes examined | < 15               | 11410(54.26%) |
|                         | ≥ 15               | 9437(44.87%) |
|                         | Unknown            | 183(0.87%) |

Table 1 The basic and clinical features of non-metastatic PDAC.

| Characteristics          | Level    | P     | Univariate analysis | Multivariate analysis |
|-------------------------|----------|-------|----------------------|-----------------------|
| Insurance Recode        |          |       |                      |                       |
|                         | Insured  | <0.001|                      |                       |
|                         | No/unknown | 1.201 | Reference            | 1.152-1.253          |
| Marital status          |          |       |                      |                       |
|                         | Married  | <0.001|                      |                       |
|                         | Reference|       | Reference            |                       |

Table 2. Univariate and multivariate analysis for OS of all patients (n=21030).
|                       | Hazard Ratio | 95% CI     |
|-----------------------|--------------|------------|
| **Single**            | 1.140        | 1.098-1.184|
| **Unknown**           | 0.985        | 0.891-1.088|
| **Age, years**        | <0.001       |            |
| <65                   | Reference    | Reference  |
| ≥65                   | 1.436        | 1.384-1.489|
| **Race recode**       | <0.001       |            |
| **White**             | Reference    | Reference  |
| **Other**             | 1.016        | 0.970-1.065|
| **Sex**               | <0.001       |            |
| **Female**            | Reference    | Reference  |
| **Male**              | 1.106        | 1.068-1.147|
| **Tumor site**        | <0.001       |            |
| Pancreas Head         | Reference    | Reference  |
| Pancreas Body Tail    | 0.704        | 0.670-0.739|
| Pancreas Other        | 0.844        | 0.795-0.897|
| **Grade**             | <0.001       |            |
| I                     | Reference    | Reference  |
| II                    | 2.409        | 2.260-2.567|
| III/IV                | 3.274        | 3.064-3.498|
| Unknown               | 1.578        | 1.449-1.719|
| **T stage**           | <0.001       |            |
| T1                    | Reference    | Reference  |
| T2                    | 1.407        | 1.335-1.483|
| T3                    | 1.595        | 1.503-1.692|
| T4                    | 2.396        | 2.192-2.620|
| **N stage**           | <0.001       |            |
|                  | Reference | Reference   |
|------------------|-----------|-------------|
| N0               | Reference | Reference   |
| N1               | 1.617     | 1.550-1.688 |
| N2               | 2.078     | 1.975-2.186 |

Treatment methods \( <0.001 \)

| Method                        | HR   | CI            |
|-------------------------------|------|---------------|
| Only surgery                  | Reference | Reference   |
| Surgery + chemotherapy        | 0.773 | 0.739-0.809   |
| Neoadjuvant radiotherapy      | 0.855 | 0.776-0.943   |
| Adjuvant radiotherapy         | 0.719 | 0.686-0.752   |

Regional nodes examined \( <0.001 \)

| Node Status | Reference | Reference |
|-------------|-----------|-----------|
| <15         | Reference | Reference |
| ≥15         | 0.828     | 0.797-0.859 |
| Unknown     | 1.133     | 0.954-1.346 |

OS: Overall Survival; CI: Confidence intervals; HR: Hazard ratios.

Table 3. Multivariate Cox analyses of treatment methods for OS (n = 21030).
| TNM Stage | Treatments               | Multivariate HR (95% CI) | P value |
|-----------|--------------------------|--------------------------|---------|
| T1-3N0M0  | Only surgery Reference   |                          | 0.001   |
|           | Surgery + chemotherapy   | 0.896(0.827-0.970)       | 0.007   |
|           | Neoadjuvant radiotherapy | 1.171(1.019-1.347)       | 0.027   |
|           | Adjuvant radiotherapy    | 0.950(0.874-1.032)       | 0.223   |
| T1-3N+M0  | Only surgery Reference   |                          | <0.001  |
|           | Surgery + chemotherapy   | 0.686(0.649-0.726)       | <0.001  |
|           | Neoadjuvant radiotherapy | 0.751(0.635-0.887)       | 0.001   |
|           | Adjuvant radiotherapy    | 0.613(0.579-0.649)       | <0.001  |
| T4N0M0    | Only surgery Reference   |                          | <0.001  |
|           | Surgery + chemotherapy   | 0.588(0.424-0.814)       | 0.001   |
|           | Neoadjuvant radiotherapy | 0.482(0.347-0.670)       | <0.001  |
|           | Adjuvant radiotherapy    | 0.858(0.621-1.185)       | 0.353   |
| T4N+M0    | Only surgery Reference   |                          | <0.001  |
|           | Surgery + chemotherapy   | 0.530(0.411-0.683)       | <0.001  |
|           | Neoadjuvant radiotherapy | 0.338(0.215-0.532)       | <0.001  |
|           | Adjuvant radiotherapy    | 0.430(0.334-0.554)       | <0.001  |

OS: Overall Survival; CI: Confidence intervals; HR: Hazard ratios.

**Table 4.** Median survival and, 1-, 3-year OS of PDAC patients (n = 21030).
| TNM Stage   | Treatments                          | Median survival | 1-year OS   | 3-year OS  |
|------------|-------------------------------------|----------------|------------|------------|
| T1-3N0M0   | Only surgery                        | 21             | 70.14%     | 46.5%      |
|            | Surgery + chemotherapy              | 25             | 73.27%     | 49.3%      |
|            | Neoadjuvant radiotherapy            | 19             | 67.65%     | 39.8%      |
|            | Adjuvant radiotherapy               | 24             | 72.09%     | 48.1%      |
| T1-3N+M0   | Only surgery                        | 10             | 38.65%     | 6.8%       |
|            | Surgery + chemotherapy              | 15             | 42.27%     | 14.8%      |
|            | Neoadjuvant radiotherapy            | 16             | 39.26%     | 12.3%      |
|            | Adjuvant radiotherapy               | 19             | 47.64%     | 18.6%      |
| T4N0M0     | Only surgery                        | 7              | 27.14%     | 6.7%       |
|            | Surgery + chemotherapy              | 17             | 47.67%     | 19.2%      |
|            | Neoadjuvant radiotherapy            | 20             | 52.75%     | 26.4%      |
|            | Adjuvant radiotherapy               | 14             | 31.82%     | 8.7%       |
| T4N+M0     | Only surgery                        | 6              | 7.28%      | 0.0%       |
|            | Surgery + chemotherapy              | 10             | 26.18%     | 6.5%       |
|            | Neoadjuvant radiotherapy            | 17             | 42.34%     | 16.5%      |
|            | Adjuvant radiotherapy               | 16             | 33.29%     | 9.8%       |

PDAC: Pancreatic Ductal Adenocarcinoma; OS: Overall Survival.

Table 5. Univariate and Multivariate Cox analyses of treatment methods for OS after PSM.
| Treatment                                      | Odds Ratio | 95% CI    | p-value |
|-----------------------------------------------|------------|-----------|---------|
| Neoadjuvant radiotherapy                      | 1.486      | 1.315-1.679 | 0.038   |
| T1-3N0M0                                      | 0.016      |            | 0.006   | 0.039   |
| Neoadjuvant radiotherapy                      |            |            | Reference | Reference | Reference |
| Adjuvant radiotherapy                         | 0.809      | 0.695-0.941 | 0.006   |
| T1-3N0M0                                      | 0.001      |            | 0.001   | 0.034   |
| Surgery plus chemotherapy                     |            |            | Reference | Reference | Reference |
| Neoadjuvant radiotherapy                      | 1.285      | 1.107-1.491 | 0.001   |
| T1-3N+M0                                      | 0.002      |            | 0.008   | 0.049   |
| Only surgery                                  |            |            | Reference | Reference | Reference |
| Neoadjuvant radiotherapy                      | 0.795      | 0.671-0.942 | 0.008   |
| T1-3N+M0                                      | 0.019      |            | 0.015   | 0.040   |
| Adjuvant radiotherapy                         |            |            | Reference | Reference | Reference |
| Neoadjuvant radiotherapy                      | 1.047      | 1.013-1.706 | 0.015   |
| T1-3N+M0                                      | 0.035      |            | 0.795   | 0.021   |
| Surgery plus chemotherapy                     |            |            | Reference | Reference | Reference |
| Neoadjuvant radiotherapy                      | 1.023      | 0.863-1.212 | 0.795   |
| T4NxM0                                        | <0.001     |            | <0.001  | <0.001  |
| Only surgery                                  |            |            | Reference | Reference | Reference |
| Neoadjuvant radiotherapy                      | 0.459      | 0.349-0.602 | <0.001  |
| T4NxM0                                        | <0.001     |            | <0.001  | 0.002   |
| Adjuvant radiotherapy                         |            |            | Reference | Reference | Reference |
| Neoadjuvant radiotherapy                      | 0.590      | 0.445-0.781 | <0.001  |
| T4NxM0     |     |     |
|------------|-----|-----|
|            | <0.001 | 0.040 | 0.028 |
| Surgery plus chemotherapy | Reference | Reference | Reference |
| Neoadjuvant radiotherapy | 0.752 | 0.573-0.987 | 0.040 |

PSM: Propensity score matching; OS: Overall Survival; CI: Confidence intervals; HR: Hazard ratios.

**Figures**

![Flowchart]( Patients with Pancreatic cancer f database (2004-2016) N=143157 N=86395 N=32221 )
Figure 1
Procedures for inclusion and exclusion of PDAC patients.
OS estimated with the Kaplan-Meier method for non-metastatic PDAC. A. OS estimated with the Kaplan-Meier method for PDAC patients with T1-3N0M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p = 0.223; surgery alone vs. neoadjuvant radiotherapy: p = 0.027; surgery alone vs. surgery plus chemotherapy: p = 0.007; adjuvant radiotherapy vs. surgery plus chemotherapy: p = 0.023). B. OS estimated with the Kaplan-Meier method for PDAC patients with T1-3N+M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p < 0.001; surgery alone vs. neoadjuvant radiotherapy: p = 0.001; surgery alone vs. surgery plus chemotherapy: p < 0.001; adjuvant radiotherapy vs. neoadjuvant radiotherapy: p = 0.017; adjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001). C. OS estimated with the Kaplan-Meier method for PDAC patients with T4N0M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p = 0.353; surgery alone vs. neoadjuvant radiotherapy: p < 0.001; surgery alone vs. surgery plus chemotherapy: p = 0.001; adjuvant radiotherapy vs. neoadjuvant radiotherapy: p < 0.001; adjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001; neoadjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001). D. OS estimated with the Kaplan-Meier method for PDAC patients with T4N+M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p = 0.353; surgery alone vs. neoadjuvant radiotherapy: p < 0.001; surgery alone vs. surgery plus chemotherapy: p < 0.001; adjuvant radiotherapy vs. neoadjuvant radiotherapy: p < 0.001; adjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001; neoadjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001).
Figure 3

The Kaplan-Meier curve of overall survival of PDAC patients after PSM. A. Comparison of OS between the neoadjuvant radiotherapy group and the only surgery group for T1-3N0M0 stage (P=0.176); B. Comparison of OS between the neoadjuvant radiotherapy group and the adjuvant radiotherapy group for T1-3N0M0 stage (P=0.125); C. Comparison of OS between the neoadjuvant radiotherapy group and the surgery plus chemotherapy group for T1-3N0M0 stage (P=0.025); D. Comparison of OS between the neoadjuvant radiotherapy group and the only surgery group for T1-3N+M0 stage (P=0.036); E. Comparison of OS between the neoadjuvant radiotherapy group and the adjuvant radiotherapy group for T1-3N+M0 stage (P=0.022); F. Comparison of OS between the neoadjuvant radiotherapy group and the surgery plus chemotherapy group for T1-3N+M0 stage (P=0.541); G. Comparison of OS between the neoadjuvant radiotherapy group and the surgery group for T4 stage (P<0.001); H. Comparison of OS between the neoadjuvant radiotherapy group and the adjuvant radiotherapy group for T4 stage (P=0.002); I. Comparison of OS between the neoadjuvant radiotherapy group and the surgery plus chemotherapy group for T4 stage (P=0.028).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- 7.docx
- 1.docx
- 2.docx
- 5.docx
- 6.docx
- 4.docx
- 3.docx
• _8.docx
• _9.docx